


CLAIMS

1. A fumarate of
(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-N-(benzo[d]oxazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide.
2. The salt according to claim 1, which is
(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-N-(benzo[d]oxazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
·hemifumarate.
3. The salt according to claim 2, which is a crystal having a diffraction angle ($2\theta \pm 0.1^\circ$) with at least two or more peaks selected from 4.5° , 5.8° , 11.2° , 12.1° , 12.4° , 13.4° , 16.6° , 17.3° , 18.2° , 20.2° , 26.4° and 27.1° , in a powder X-ray diffraction spectrum.
4. The salt according to claim 2 or 3, which is a crystal having a diffraction angle ($2\theta \pm 0.1^\circ$) with at least five or more peaks selected from 4.5° , 5.8° , 11.2° , 12.1° , 12.4° , 13.4° , 16.6° , 17.3° , 18.2° , 20.2° , 26.4° and 27.1° , in a powder X-ray diffraction spectrum.
5. The salt according to any one of claims 2 to 4, which is a crystal having a diffraction angle ($2\theta \pm 0.1^\circ$) with peaks at 4.5° , 5.8° , 11.2° , 12.1° , 12.4° , 13.4° , 16.6° , 17.3° , 18.2° , 20.2° , 26.4° and 27.1° , in a powder X-ray diffraction spectrum.

6. The salt according to any one of claims 2 to 5, which is a crystal having a powder X-ray diffraction spectrum as shown in the following Fig. 2.

Fig. 2



7. The salt according to any one of claims 2 to 6, which is a crystal having a peak temperature in a differential scanning calorie (DSC) curve with an endothermic peak in the vicinity of from 197°C to 199°C.

8. The salt according to claim 1, which is
(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-N-(benzo[d]oxazol-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide·monofumara
te.

9. The salt according to claim 8, which is a crystal having a diffraction angle ($2\theta \pm 0.1^\circ$) with at least two or more peaks selected from 7.2°, 12.4°, 14.4°, 15.0°, 15.6°, 19.0°, 22.3°,


22.6°, 23.4°, 25.5°, 25.9° and 27.6°, in a powder X-ray diffraction spectrum.

10. The salt according to claim 8 or 9, which is a crystal having a diffraction angle ($2\theta \pm 0.1^\circ$) with at least five or more peaks selected from 7.2°, 12.4°, 14.4°, 15.0°, 15.6°, 19.0°, 22.3°, 22.6°, 23.4°, 25.5°, 25.9° and 27.6°, in a powder X-ray diffraction spectrum.

11. The salt according to any one of claims 8 to 10, which is a crystal having a diffraction angle ($2\theta \pm 0.1^\circ$) with peaks at 7.2°, 12.4°, 14.4°, 15.0°, 15.6°, 19.0°, 22.3°, 22.6°, 23.4°, 25.5°, 25.9° and 27.6°, in a powder X-ray diffraction spectrum.

12. The salt according to any one of claims 8 to 11, which is a crystal having a powder X-ray diffraction spectrum as shown in the following Fig. 4.

Fig. 4




13. The salt according to any one of claims 8 to 12, which is a crystal having a peak temperature in a differential scanning calorimetric (DSC) curve with an endothermic peak in the vicinity of from 219°C to 224°C.

14. The salt according to claim 8, which is in an amorphous form exhibiting a halo pattern in the powder X-ray diffraction spectrum.

15. The salt according to claim 8 or 14, which is in an amorphous form, having a powder X-ray diffraction spectrum as shown in the following Fig. 1.

Fig. 1



16. A BTK inhibitor comprising the salt according to any one of claims 1 to 15 as an active ingredient.

17. A pharmaceutical composition comprising the salt according to any one of claims 1 to 15.

18. An anti-tumor agent or a preventive and/or therapeutic agent for an allergic disease, an autoimmune disease, or an inflammatory disease, comprising the salt according to any one of claims 1 to 15 as an active ingredient.

19. An anti-tumor agent against a hematologic tumor or a preventive and/or therapeutic agent for allergic rhinitis, pollinosis, atopic dermatitis, rheumatoid arthritis and systemic lupus erythematosus, comprising the salt according to any one of claims 1 to 15 as an active ingredient.

20. Use of the salt according to any one of claims 1 to 15, for a production of a BTK inhibitor.

21. Use of the salt according to any one of claims 1 to 15, for a production of a pharmaceutical composition.

22. Use of the salt according to any one of claims 1 to 15, for a production of an anti-tumor agent or a preventive and/or therapeutic agent for an allergic disease, an autoimmune disease or an inflammatory disease.

23. Use of the salt according to any one of claims 1 to 15, for a production of an anti-tumor agent against a hematologic tumor or a preventive and/or therapeutic agent for allergic

rhinitis, pollinosis, atopic dermatitis, rheumatoid arthritis and systemic lupus erythematosus.

24. The salt according to any one of claims 1 to 15 for use in a BTK inhibition.

25. The salt according to any one of claims 1 to 15 for use as a medicine.

26. The salt according to any one of claims 1 to 15 for use in prevention or treatment of a tumor, an allergic disease, an autoimmune disease or an inflammatory disease.

27. The salt according to any one of claims 1 to 15 for use in prevention or treatment of a hematologic tumor, allergic rhinitis, pollinosis, atopic dermatitis, rheumatoid arthritis or systemic lupus erythematosus.